Search Results (7)

Background/Objectives: The PEER beamline at the ANSTO Australian Synchrotron has been developed to enable VHEE FLASH radiotherapy studies, both dosimetric and biological. Featuring a 100 MeV electron linac, it delivers single or multi-pulse irradiations consisting of 100 ps bunches with a 2 ns spacing, resulting in average dose-rates and instantaneous dose-rates as high as ${10}^8$ Gy/s and ${10}^9$ Gy/s, respectively. Much work has been conducted to realise a stable accelerator facility, complete with the tooling and diagnostics required to undertake such studies. However, to truly confirm its suitability required a successful biological benchmarking. Methods: Three cell lines were irradiated utilising real-time dosimetry to compare linear quadratic cell survival curves with other facilities. Also, mouse cadavers were transported and irradiated, mimicking live animals, to assess the feasibility and logistics of small animal experiments. Results: By comparing the trends of the linear quadratic model, evident in the $\alpha$ and $\beta$ parameters, the PEER cell survival results were shown to be in agreement with VHEE results from the ARES beamline at DESY, Hamburg, Germany. Evident in the survival trends, VHEE produced more cell sparing in all cell lines compared to 2 Gy/s X-rays delivered on the IMBL, another beamline at the Australian Synchrotron. The results of the mouse cadaver irradiations showed that PEER can safely and efficiently irradiate small animals. Conclusions: The PEER beamline is shown to possess suitable capabilities, including real-time dosimetry, repeatable alignment, and linac diagnostics, rendering it suitable for future in vivo VHEE UHDR FLASH radiotherapy investigations. Full article

Laser-accelerated electron beams, in the so-called Very High-Energy Electron (VHEE) energy range, are of great interest for biomedical applications. For instance, laser-driven VHEE beams are envisaged to offer suitable compact accelerators for the promising field of FLASH radiotherapy. Radiobiology experiments carried out using laser-driven beams require the real-time knowledge of the dose delivered to the sample. We have developed an online dose monitoring procedure, using an Integrating Current Transformer (ICT) coupled to a suitable collimator, that allows the estimation of the delivered dose on a shot-to-shot basis under suitable assumptions. The cross-calibration of the measured charge with standard offline dosimetry measurements carried out with RadioChromic Films (RCFs) is discussed, demonstrating excellent correlation between the two measurements. Full article

Very-high-energy electron (VHEE) beams, ranging from 50 to 300 or 400 MeV, are the subject of intense research investigation, with considerable interest concerning applications in radiation therapy due to their accurate energy deposition into large and deep-seated tissues, sharp beam edges, high sparing properties, and minimal radiation effects on normal tissues. The very-high-energy electron beam, which ranges from 50 to 400 MeV, and Ultra-High-Energy Electron beams up to 1–2 GeV, are considered extremely effective for human tumor therapy while avoiding the spatial requirements and cost of proton and heavy ion facilities. Many research laboratories have developed advanced testing infrastructures with VHEE beams in Europe, the USA, Japan, and other countries. These facilities aim to accelerate the transition to clinical application, following extensive simulations for beam transport that support preclinical trials and imminent clinical deployment. However, the clinical implementation of VHEE for FLASH radiation therapy requires advances in several areas, including the development of compact, stable, and efficient accelerators; the definition of sophisticated treatment plans; and the establishment of clinically validated protocols. In addition, the perspective of VHEE for accessing ultra-high dose rate (UHDR) dosimetry presents a promising procedure for the practical integration of FLASH radiotherapy for deep tumors, enhancing normal tissue sparing while maintaining the inherent dosimetry advantages. However, it has been proven that a strong effort is necessary to improve the main operational accelerator conditions, ensuring a stable beam over time and across space, as well as compact infrastructure to support the clinical implementation of VHEE for FLASH cancer treatment. VHEE-accessing ultra-high dose rate (UHDR) perspective dosimetry is integrated with FLASH radiotherapy and well-prepared cancer treatment tools that provide an advantage in modern oncology regimes. This study explores technological progress and the evolution of electron accelerator beam energy technology, as simulated by the ASTRA code, for developing VHEE and UHEE beams aimed at medical applications. FLUKA code simulations of electron beam provide dose distribution plots and the range for various energies inside the phantom of PMMA. Full article

Very-high-energy electrons, coupled with ultra-high dose rates, are being explored for their potential use in radiotherapy to treat deep-seated tumours. The dose per pulse needed to achieve ultra-high dose rates far exceeds the limit of current medical linear accelerator capabilities. A high dose per pulse has been observed as the limiting factor for many existing dosimeters, resulting in saturation at doses far below what is required. The MOSkin, an existing clinical quality assurance dosimeter, has previously been demonstrated as dose rate independent but has not been subjected to a high dose per pulse. Within this study, the MOSkins dose-per-pulse response was tested for linearity, with a dose per pulse as high as 23 Gy within 200 ns at the ANSTO Australian Synchrotron’s Pulsed Energetic Electrons for Research facility. While using EBT-XD film as a reference dosimeter, a dose rate dependence of the EBT-XD was discovered. Once confirmed and a correction factor established, EBT-XD was used as an independent reference measurement. This work presents confirmation of the MOSkin suitability for ultra-high dose-rate environments with an electron energy of 100 MeV, and a theoretical discussion of its dose-rate and dose-per-pulse independence; the MOSkin is the only detector suitable for both clinical quality assurance, and ultra-high dose-rate measurements in its standard, unmodified form. Full article

Metallic implants in radiotherapy patients alter dose distributions due to their high density and unique composition, potentially compromising treatment precision. This study evaluates the effects of three metallic materials, Co-Cr-Mo alloy, titanium alloy, and stainless steel, on dose distribution across four radiotherapy modalities: 6 MV photons, 15 MeV electrons, 170 MeV protons, and very-high-energy electrons (100 and 150 MeV). Monte Carlo simulations in the TOol for PArticle Simulations Monte Carlo (TOPAS MC) generated percentage depth dose curves and dose profiles, with dosage data standardized to a reference point and uncertainties addressed via error propagation. Results revealed that the Co-Cr-Mo alloy produced the most significant alterations. For instance, at 100 MeV Very High Electron Energy (VHEE), the dose at a 15 cm depth was 34.57% lower than in water; 6 MV photons showed a 15.16% reduction, and the proton Bragg peak shifted 9.5 cm closer to the source. These pronounced changes along the central beam axis affected dose distributions anterior and posterior to the metal. A prostate cancer simulation further demonstrated considerable dose reduction with deeply embedded metallic implants. The findings underscore the critical impact of implant properties on radiotherapy dose distributions, emphasizing the need to integrate these factors into clinical protocols to improve dosimetric accuracy and treatment safety. Full article

The use of very high energy electron (VHEE) beams, with energies between 50 and 400 MeV, has drawn considerable interest in radiotherapy due to their deep tissue penetration, sharp beam edges, and low sensitivity to tissue density. VHEE beams can be precisely steered with magnetic components, positioning VHEE therapy as a cost-effective option between photon and proton therapies. However, the clinical implementation of VHEE therapy (VHEET) requires advances in several areas: developing compact, stable, and efficient accelerators; creating sophisticated treatment planning software; and establishing clinically validated protocols. In addition, the perspective of VHEE to access ultra-high dose–rate regime presents a promising avenue for the practical integration of FLASH radiotherapy of deep tumors and metastases with VHEET (FLASH-VHEET), enhancing normal tissue sparing while maintaining the inherent dosimetric advantages of VHEET. However, FLASH-VHEET systems require validation of time-dependent dose parameters, thus introducing additional technological challenges. Here, we discuss recent progress in VHEET research, focusing on both conventional and FLASH modalities, and covering key aspects including dosimetric properties, radioprotection, accelerator technology, beam focusing, radiobiological effects, and clinical outcomes. Furthermore, we comprehensively analyze initial VHEET in silico studies on coverage across various tumor sites. Full article

The development of innovative approaches that would reduce the sensitivity of healthy tissues to irradiation while maintaining the efficacy of the treatment on the tumor is of crucial importance for the progress of the efficacy of radiotherapy. Recent methodological developments and innovations, such as scanned beams, ultra-high dose rates, and very high-energy electrons, which may be simultaneously available on new accelerators, would allow for possible radiobiological advantages of very short pulses of ultra-high dose rate (FLASH) therapy for radiation therapy to be considered. In particular, very high-energy electron (VHEE) radiotherapy, in the energy range of 100 to 250 MeV, first proposed in the 2000s, would be particularly interesting both from a ballistic and biological point of view for the establishment of this new type of irradiation technique. In this review, we examine and summarize the current knowledge on VHEE radiotherapy and provide a synthesis of the studies that have been published on various experimental and simulation works. We will also consider the potential for VHEE therapy to be translated into clinical contexts. Full article